NVIDIA
NVDA
Tesla
TSLA
Super Micro Computer
SMCI
4
Palantir
PLTR
5
Hims & Hers Health
HIMS
US Stock MarketDetailed Quotes
ANNX Annexon
- 2.580
- -0.070-2.64%
Close Feb 25 16:00 ET
- 2.580
- 0.0000.00%
Post 20:01 ET
275.01MMarket Cap-2.50P/E (TTM)
2.690High2.535Low1.12MVolume2.630Open2.650Pre Close2.89MTurnover1.42%Turnover RatioLossP/E (Static)106.59MShares8.40052wk High0.83P/B202.98MFloat Cap2.53552wk Low--Dividend TTM78.67MShs Float38.010Historical High--Div YieldTTM5.85%Amplitude1.570Historical Low2.581Avg Price1Lot Size
Annexon Stock Forum
Who is loading up?
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Annexon (ANNX) announced positive topline results from a real-world evidence study comparing ANX005 treatment to IVIg/PE for Guillain-Barré Syndrome (GBS). The study matched 79 ANX005-treated patients from Phase 3 trials with 79 real-wo...
4 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in Interna...
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon presented new Phase 2 datafor ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Ke...
((((((. ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 )))))
*ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025
*ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...
No comment yet